Medtronic's Evolut Playbook: Stabilization Through Updated Durability Messaging

Research evidence excerpt

Medtronic's Evolut Playbook: Stabilization Through Updated Durability Messaging

Medical Supplies & Devices: Cardiovascular

Medtronic

TD SECURITIES (USA) LLC COMPANY UPDATE

June 30, 2026

Price: $80.93 (06/29/2026) Medtronic's Evolut Playbook: Stabilization

Price Target: $119.00 Through Updated Durability Messaging

BUY (1)

Joshua Jennings, M.D. THE TD COWEN INSIGHT

646 562 1333

MDT entered NY Valves contending that U.S. TAVR share and procedure trends have stabilized

joshua.jennings@tdsecurities.com

following the Evolut durability controversy. Through late-breaker presentations and a

John Rusch, CFA sponsored symposium, the company advanced its defense that excess reinterventions in

646 562 1324 Evolut Low Risk reflected the aggressive post-dilation of a legacy valve rather than an intrinsic

john.rusch@tdsecurities.com

design flaw.

Colin Clark

646 562 1441 Medtronic arrived at NY Valves with a coordinated strategy to stabilize physician confidence

colin.clark@tdsecurities.com in the Evolut franchise. Following commentary on its F4Q26 earnings call that U.S. TAVR share

Key Data and weekly procedure volumes had stabilized over the preceding eight to ten weeks, the

Symbol NYSE: MDT company used the meeting to reinforce its evolving durability narrative through late-breaking

Beta: 0.60 scientific presentations and a sponsored lunch symposium. The central message was that

52-Week Range: $105.35-$73.75 the elevated reintervention rate observed at six- and seven-year (preliminary analysis) follow-

up in the Evolut Low Risk trial should be viewed as a consequence of aggressive post-dilation

Market Cap: $103.6B

techniques used with a legacy-generation Evolut valve rather than an inherent limitation of

Net Debt (MM): $19,928.0

the self-expanding platform.